The Impact of Simultaneous Td and HB Vaccination on HBS Antibody Titer in Dialysis Patients

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Nephrology, School of Medicine and Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Assistant Professor, Department of Nephrology, School of Medicine and Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Nurse, Dialysis Department, Alzaha Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

6 Head of Enviromental Health Department, Alzaha Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Antibody production in patients with end-stage kidney disease impairs due to several mechanisms. There are different ways to improve response rate to Hepatitis B (HB) vaccine. In this study we evaluated the effect of Tetanus-diphtheria toxoid (Td) vaccine on HBS Antibody (Ab) level while being given simultaneously with HB vaccine. Methods: We recruited 43 hemodialysis and 20 peritoneal dialysis patients who had HBS Ab titer less than 10 IU/L after first schedule of HB vaccination. The patients were divided into two groups: A (30 patients) and B (33 patients). Both received 3 dose HB vaccination schedule of 40 µg intramuscularly in the left deltoid muscle at 0, 1 and 6 months while group A, received Td vaccine intramuscularly simultaneous with first dose of HB vaccine, too. HBS Ab was measured in periods of 1 and 6 months after completion of vaccination.Finding: Group A had better but not significant response rate than group B in one month (96% vs. 83.9%) (P = 0.07) and six months (87.5% vs 83.3%) (P = 0.34) after completion of vaccination. Patients with HCV infection had lower response rate than the ones who did not have HCV infection (33.3% vs. 92.5%) (P= 0.02). Response rate was better in younger patients (r= 0.339 and P= 0.005). Conclusion: The use of Td vaccine simultaneous with HB vaccination does not have any role in the persistence of immune response. Age and HCV infection negatively affect the response to HB vaccination in dialysis patients. 

Keywords

References

  1. Agrawal S, Gollapudi P, Elahimehr R, Pahl MV, Vaziri ND. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Neph-rol Dial Transplant 2010; 25(3): 737-46.
  2. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage re-nal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25(1): 205-12.
  3. Ocak S, Eskiocak AF. The evaluation of im-mune responses to hepatitis B vaccination in di-abetic and non-diabetic haemodialysis patients and the use of tetanus toxoid. Nephrology (Carl-ton) 2008; 13(6): 487-91.
  4. Himmelfarb J, Chuang P, Schulman G. Hemodi-alysis. In: Brenner BM, Rector FC, Editors. Brenner and Rector's The Kidney. 8th ed. Phila-delphia: Saunders Elsevier; 2007. p. 1193-4.
  5. Ibrahim S, el-Din S, Bazzal I. Antibody level after hepatitis-B vaccination in hemodialysis pa-tients: impact of dialysis adequacy, chronic in-flammation, local endemicity and nutritional status. J Natl Med Assoc 2006; 98(12): 1953-7.
  6. Ramezani A, Velayati AA, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, et al. Persis-tence of hepatitis B vaccine immunity in hemo-dialysis patients. Ther Apher Dial 2008; 12(2): 143-6.
  7. Buti M, Viladomiu L, Jardi R, Olmos A, Rodri-guez JA, Bartolome J, et al. Long-term immuno-genicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992; 12(3): 144-7.
  8. Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vac-cination in hemodialysis patients. Vaccine 2004; 22(29-30): 3963-7.
  9. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vac-cination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16(2): 95-7.
  10. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to hepatitis B vaccination in pa-tients on hemodialysis and peritoneal dialysis. Vaccine 2005; 23(30): 3957-60.
  11. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vac-cination. Clin Nephrol 2007; 68(4): 228-34.
  12. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogen-icity and protective efficacy against hepatitis B. Drugs 2003; 63(10): 1021-51.
  13. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly he-modialysis (HD) patients? Clin Nephrol 2002; 58(4): 301-4.
  14. Kovacic V, Sain M, Vukman V. Efficient hae-modialysis improves the response to hepatitis B virus vaccination. Intervirology 2002; 45(3): 172-6.
  15. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutri-tion and its importance as a risk factor for mor-bidity and mortality. Nephrol Dial Transplant 1996; 11(8): 1559-63.
  16. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitis B vac-cination in hemodialysis patients. Artif Organs 2002; 26(6): 492-6.
  17. Perez-Garcia R, Perez-Garcia A, Verbeelen D, Bernstein ED, Villarrubia VG, Alvarez-Mon M. AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int 2002; 61(5): 1845-52.
  18. Singh NP, Mandal SK, Thakur A, Kapoor D, Anuradha S, Prakash A, et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure--results of a prospective, randomized trial. Ren Fail 2003; 25(2): 255-66.
  19. Kapoor D, Aggarwal SR, Singh NP, Thakur V, Sarin SK. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hep-atitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999; 6(5): 405-9.
  20. Sonmez E, Sonmez AS, Bayindir Y, Coskun D, Ariturk S. Antihepatitis B response to hepatitis B vaccine administered simultaneously with teta-nus toxoid in nonresponder individuals. Vaccine 2002; 21(3-4): 243-6.
  21. Fabrizi F, Andrulli S, Bacchini G, Corti M, Loca-telli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialy-sis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12(6): 1204-11.
  22. Bouts AH, Davin JC, Krediet RT, Monnens LA, Nauta J, Schroder CH, et al. Children with chron-ic renal failure have reduced numbers of memory B cells. Clin Exp Immunol 2004; 137(3): 589-94.
Journal of Isfahan Medical School
Volume 29, Issue 126 - Serial Number 126
January and February 2011
Pages 56-64

Files

History

  • Receive Date: 28 December 2010
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics